{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:23:11Z","timestamp":1788322991796,"version":"build-2803163510"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05825-3","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T08:58:48Z","timestamp":1744016328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Artificial intelligence to predict treatment response in rheumatoid arthritis and spondyloarthritis: a scoping review"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-5330","authenticated-orcid":false,"given":"Diego","family":"Benavent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2551","authenticated-orcid":false,"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7525-4492","authenticated-orcid":false,"given":"Jose Francisco","family":"Garc\u00eda Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-7044","authenticated-orcid":false,"given":"Mar\u00eda","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-5126","authenticated-orcid":false,"given":"Susan","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-7146","authenticated-orcid":false,"given":"Teresa","family":"Ot\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4607-9178","authenticated-orcid":false,"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8674-6692","authenticated-orcid":false,"given":"Antonio","family":"G\u00f3mez-Centeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"5","key":"5825_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.reumae.2022.08.006","volume":"19","author":"E Loza","year":"2023","unstructured":"Loza E, Plazuelo P, Ceade, (2023) Patients with spondyloarthritis including psoriatic arthritis: current needs, impact, and perspective. Reumatol Clin (Engl Ed) 19(5):273\u2013278. https:\/\/doi.org\/10.1016\/j.reumae.2022.08.006","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"5825_CR2","doi-asserted-by":"publisher","first-page":"1478376","DOI":"10.3389\/fpubh.2024.1478376","volume":"12","author":"Y Song","year":"2024","unstructured":"Song Y, Chen Y, Wen L et al (2024) Health-related quality of life profiles in patients with rheumatoid arthritis: a latent profile analysis. Front Public Health 12:1478376. https:\/\/doi.org\/10.3389\/fpubh.2024.1478376","journal-title":"Front Public Health"},{"issue":"11","key":"5825_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-082966","volume":"14","author":"C Chen","year":"2024","unstructured":"Chen C, Shi Q, He W et al (2024) Global trends in the burden of rheumatoid arthritis by sociodemographic index: a joinpoint and age-period-cohort analysis based on the Global Burden of Disease Study 2019. BMJ Open 14(11):e082966. https:\/\/doi.org\/10.1136\/bmjopen-2023-082966","journal-title":"BMJ Open"},{"issue":"1","key":"5825_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q et al (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther 19(1):92. https:\/\/doi.org\/10.1186\/s13075-017-1293-1","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5825_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/acr.24834","volume":"74","author":"E Myasoedova","year":"2022","unstructured":"Myasoedova E, Athreya AP, Crowson CS et al (2022) Toward individualized prediction of response to methotrexate in early rheumatoid arthritis: a pharmacogenomics-driven machine learning approach. Arthritis Care Res (Hoboken) 74(6):879\u2013888. https:\/\/doi.org\/10.1002\/acr.24834","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5825_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152329","volume":"64S","author":"MJ Lewis","year":"2024","unstructured":"Lewis MJ (2024) Predicting best treatment in rheumatoid arthritis. Semin Arthritis Rheum 64S:152329. https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152329","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5825_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","volume":"8","author":"H Arksey","year":"2005","unstructured":"Arksey H, O\u2019Malley L (2005) Scoping studies: towards a methodological framework. Int J Soc Res Methodol 8(1):19\u201332. https:\/\/doi.org\/10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"issue":"7","key":"5825_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W et al (2018) PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 169(7):467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"5825_CR9","unstructured":"(2024) Use of artificial intelligence to identify predictive factors of response to treatment in rheumatoid arthritis and spondyloarthritis: a scoping review. https:\/\/figshare.com\/account\/home#\/projects\/228819"},{"issue":"1","key":"5825_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","volume":"170","author":"RF Wolff","year":"2019","unstructured":"Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S (2019) PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. Ann Intern Med 170(1):51\u201358. https:\/\/doi.org\/10.7326\/M18-1376","journal-title":"Clin Rheumatol"},{"key":"5825_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/annrheumdis-2023-eular.3265","volume":"82","author":"A Alsaber","year":"2023","unstructured":"Alsaber A, Al-Herz A, Alawadhi B et al (2023) Identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics using machine learning model. Ann Rheum Dis 82:567. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.3265","journal-title":"Ann Rheum Dis"},{"key":"5825_CR12","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1002\/art.42355","volume":"74","author":"N Aripova","year":"2022","unstructured":"Aripova N, Reed G, England B et al (2022) An expanded anti-citrullinated protein antibody profile derived using unsupervised machine learning predicts treatment responses to biologic therapies in rheumatoid arthritis. Arthritis Rheumatol 74:3185\u20133186. https:\/\/doi.org\/10.1002\/art.42355","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"5825_CR13","first-page":"6524","volume":"15","author":"J Bai","year":"2023","unstructured":"Bai J, Tian Y, Wang F et al (2023) Role of systemic immune-inflammation index (SII) in assessing clinical efficacy of TNF-\u03b1 inhibitors for rheumatoid arthritis. Am J Transl Res 15(11):6524\u20136533","journal-title":"Am J Transl Res"},{"key":"5825_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/annrheumdis-2022-eular.2658","volume":"81","author":"V Bouget","year":"2022","unstructured":"Bouget V, Duquesne J, Courn\u00e8de PH et al (2022) Machine learning predicts response to methotrexate in rheumatoid arthritis: results on the espoir, T-reach and Leiden cohorts. Ann Rheum Dis 81:535. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.2658","journal-title":"Ann Rheum Dis"},{"key":"5825_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002442","author":"V Bouget","year":"2022","unstructured":"Bouget V, Duquesne J, Hassler S et al (2022) Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002442","journal-title":"RMD Open"},{"key":"5825_CR16","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1136\/annrheumdis-2019-eular.5049","volume":"78","author":"F Brizzi","year":"2019","unstructured":"Brizzi F, Khan SA, Prunotto M et al (2019) An integrated proteomics and antibody analysis of the U-Act-Early trial to identify markers of treatment response and disease progression in early rheumatoid arthritis. Ann Rheum Dis 78:1574. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.5049","journal-title":"Ann Rheum Dis"},{"key":"5825_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/pds.5518","volume":"31","author":"T Burkard","year":"2022","unstructured":"Burkard T, Kalweit M, Burden A et al (2022) Patient groups in rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic disease modifying antirheumatic drugs. Pharmacoepidemiol Drug Saf 31:35. https:\/\/doi.org\/10.1002\/pds.5518","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5825_CR18","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/art.42355","volume":"74","author":"G Casaburi","year":"2022","unstructured":"Casaburi G, O\u2019Malley T, Holscher T et al (2022) Targeted synovial tissue RNA-Seq coupled with artificial intelligence accurately predicts early rheumatoid arthritis patients likely to respond to CsDMARDs, enriching CsDMARDs response rates and enabling early identification of patients requiring subsequent biological therapy. Arthritis Rheumatol 74:1846. https:\/\/doi.org\/10.1002\/art.42355","journal-title":"Arthritis Rheumatol"},{"key":"5825_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109026","volume":"116","author":"J Chen","year":"2019","unstructured":"Chen J, Tang MS, Xu LC et al (2019) Proteomic analysis of biomarkers predicting the response to triple therapy in patients with rheumatoid arthritis. Biomed Pharmacother 116:109026. https:\/\/doi.org\/10.1016\/j.biopha.2019.109026","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5825_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000488519","volume":"83","author":"S Cherlin","year":"2017","unstructured":"Cherlin S, Cordell HJ (2017) Prediction of treatment response from genome-wide SNP data in rheumatoid arthritis patients. Hum Hered 83(1):5. https:\/\/doi.org\/10.1159\/000488519","journal-title":"Hum Hered"},{"key":"5825_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.trsl.2024.07.001","volume":"273","author":"A Cho","year":"2024","unstructured":"Cho A, Ahn J, Kim A et al (2024) A multi-biomarker panel for predicting tocilizumab response in rheumatoid arthritis patients. Transl Res 273:23\u201331. https:\/\/doi.org\/10.1016\/j.trsl.2024.07.001","journal-title":"Transl Res"},{"issue":"3","key":"5825_CR22","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","volume":"8","author":"S Cohen","year":"2021","unstructured":"Cohen S, Wells AF, Curtis JR et al (2021) A molecular signature response classifier to predict inadequate response to tumor necrosis factor-\u03b1 inhibitors: the NETWORK-004 prospective observational study. Rheumatol Ther 8(3):1159\u20131176. https:\/\/doi.org\/10.1007\/s40744-021-00330-y","journal-title":"Rheumatol Ther"},{"issue":"4","key":"5825_CR23","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40744-023-00568-8","volume":"10","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yun H, Chen L et al (2023) Real-world sarilumab use and rule testing to predict treatment response in patients with rheumatoid arthritis: findings from the RISE registry. Rheumatol Ther 10(4):1055\u20131072. https:\/\/doi.org\/10.1007\/s40744-023-00568-8","journal-title":"Rheumatol Ther"},{"issue":"10","key":"5825_CR24","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1007\/s12325-023-02600-3","volume":"40","author":"J Dal\u00e9n","year":"2023","unstructured":"Dal\u00e9n J, Svedbom A, Hernlund E et al (2023) Identifying predictors of first-line subcutaneous TNF-inhibitor persistence in patients with inflammatory arthritis: a decision tree analysis by indication. Adv Ther 40(10):4657\u20134674. https:\/\/doi.org\/10.1007\/s12325-023-02600-3","journal-title":"Adv Ther"},{"issue":"1","key":"5825_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e32834d3e0b","volume":"22","author":"T Dervieux","year":"2012","unstructured":"Dervieux T, Wessels JAM, Kremer JM et al (2012) Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genom 22(1):1\u20139. https:\/\/doi.org\/10.1097\/FPC.0b013e32834d3e0b","journal-title":"Pharmacogenet Genom"},{"key":"5825_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02851-5","author":"SQ Duong","year":"2022","unstructured":"Duong SQ, Crowson CS, Athreya A et al (2022) Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/s13075-022-02851-5","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"5825_CR27","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/rheumatology\/keac645","volume":"62","author":"J Duquesne","year":"2023","unstructured":"Duquesne J, Bouget V, Courn\u00e8de PH et al (2023) Machine learning identifies a profile of inadequate responder to methotrexate in rheumatoid arthritis. Rheumatology (United Kingdom) 62(7):2402\u20132409. https:\/\/doi.org\/10.1093\/rheumatology\/keac645","journal-title":"Rheumatology (United Kingdom)"},{"key":"5825_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1136\/annrheumdis-2023-eular.1550","volume":"82","author":"S Fadaei","year":"2023","unstructured":"Fadaei S, Welsing P, Spierings J (2023) Using the potential-outcomes framework to predict added value of more intensive initial therapy for individual early RA patients. Ann Rheum Dis 82:594\u2013595. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.1550","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5825_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/acr.25048","volume":"75","author":"C Fern\u00e1ndez-Carballido","year":"2023","unstructured":"Fern\u00e1ndez-Carballido C, Sanchez-Piedra C, Valls R et al (2023) Female sex, age, and unfavorable response to tumor necrosis factor inhibitors in patients with axial spondyloarthritis: results of statistical and artificial intelligence-based data analyses of a national multicenter prospective registry. Arthritis Care Res 75(1):115\u2013124. https:\/\/doi.org\/10.1002\/acr.25048","journal-title":"Arthritis Care Res"},{"key":"5825_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.815881","author":"A Garc\u00eda-Dorta","year":"2021","unstructured":"Garc\u00eda-Dorta A, Le\u00f3n-Suarez P, Pe\u00f1a S et al (2021) Association of gender, diagnosis, and obesity with retention rate of secukinumab in spondyloarthropathies: results form a multicenter real-world study. Front Med. https:\/\/doi.org\/10.3389\/fmed.2021.815881","journal-title":"Front Med"},{"key":"5825_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11010044","author":"HR Gosselt","year":"2021","unstructured":"Gosselt HR, Verhoeven MMA, Bulatovi\u0107-\u0106alasan M et al (2021) Complex machine-learning algorithms and multivariable logistic regression on par in the prediction of insufficient clinical response to methotrexate in rheumatoid arthritis. J Pers Med. https:\/\/doi.org\/10.3390\/jpm11010044","journal-title":"J Pers Med"},{"issue":"6","key":"5825_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/RHU.0000000000001302","volume":"27","author":"AB Gottlieb","year":"2021","unstructured":"Gottlieb AB, Mease PJ, Kirkham B et al (2021) Secukinumab efficacy in psoriatic arthritis: machine learning and meta-analysis of four phase 3 trials. J Clin Rheumatol 27(6):239\u2013247. https:\/\/doi.org\/10.1097\/RHU.0000000000001302","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"5825_CR33","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/art.41056","volume":"71","author":"Y Guan","year":"2019","unstructured":"Guan Y, Zhang H, Quang D et al (2019) Machine learning to predict anti-tumor necrosis factor drug responses of rheumatoid arthritis patients by integrating clinical and genetic markers. Arthritis Rheumatol 71(12):1987\u20131996. https:\/\/doi.org\/10.1002\/art.41056","journal-title":"Arthritis Rheumatol"},{"key":"5825_CR34","doi-asserted-by":"publisher","first-page":"1303231","DOI":"10.3389\/fimmu.2023.1303231","volume":"14","author":"I Hageman","year":"2023","unstructured":"Hageman I, Mol F, Atiqi S et al (2023) Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients. Front Immunol 14:1303231. https:\/\/doi.org\/10.3389\/fimmu.2023.1303231","journal-title":"Front Immunol"},{"issue":"7","key":"5825_CR35","doi-asserted-by":"publisher","first-page":"S593","DOI":"10.1016\/j.jval.2022.04.1612","volume":"25","author":"Z Icten","year":"2022","unstructured":"Icten Z, Starzyk K, Friedman M et al (2022) RWD88 prediction of non-response to first-line methotrexate treatment in rheumatoid arthritis: a real-world data analysis using machine learning. Value Health 25(7):S593. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1612","journal-title":"Value Health"},{"key":"5825_CR36","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/art.41966","volume":"73","author":"Y Jin","year":"2021","unstructured":"Jin Y, Landon J, Krueger W et al (2021) Predicting treatment change in rheumatoid arthritis patients treated with tnf inhibitors as first-line biologic agent. Arthritis Rheumatol 73:1176\u20131178. https:\/\/doi.org\/10.1002\/art.41966","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"5825_CR37","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3899\/jrheum.201626","volume":"48","author":"FD Johansson","year":"2021","unstructured":"Johansson FD, Collins JE, Yau V et al (2021) Predicting response to tocilizumab monotherapy in rheumatoid arthritis: a real-world data analysis using machine learning. J Rheumatol 48(9):1364\u20131370. https:\/\/doi.org\/10.3899\/jrheum.201626","journal-title":"J Rheumatol"},{"key":"5825_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/annrheumdis-2021-eular.1107","volume":"80","author":"S Ju","year":"2021","unstructured":"Ju S, Hudson M, Colmegna I et al (2021) Predicting responses to anti-tnf treatments in rheumatoid arthritis patients from genetic and clinical data using a machine learning approach. Ann Rheum Dis 80:10\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.1107","journal-title":"Ann Rheum Dis"},{"key":"5825_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1011073","author":"M Kalweit","year":"2023","unstructured":"Kalweit M, Burden AM, Boedecker J et al (2023) Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs. PLoS Comput Biol. https:\/\/doi.org\/10.1371\/journal.pcbi.1011073","journal-title":"PLoS Comput Biol"},{"key":"5825_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252116","author":"M Kato","year":"2021","unstructured":"Kato M, Ikeda K, Sugiyama T et al (2021) Associations of ultrasound-based inflammation patterns with peripheral innate lymphoid cell populations, serum cytokines\/chemokines, and treatment response to methotrexate in rheumatoid arthritis and spondyloarthritis. PLoS\u00a0One. https:\/\/doi.org\/10.1371\/journal.pone.0252116","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"5825_CR41","doi-asserted-by":"publisher","first-page":"20169","DOI":"10.1038\/s41598-021-99625-x","volume":"11","author":"W Kim","year":"2021","unstructured":"Kim W, Kim TH, Oh SJ et al (2021) Association of TLR 9 gene polymorphisms with remission in patients with rheumatoid arthritis receiving TNF-\u03b1 inhibitors and development of machine learning models. Sci Rep 11(1):20169. https:\/\/doi.org\/10.1038\/s41598-021-99625-x","journal-title":"Sci Rep"},{"issue":"5","key":"5825_CR42","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s12026-023-09382-4","volume":"71","author":"W Kim","year":"2023","unstructured":"Kim W, Yeon HR, Kim JH et al (2023) Association between SYVN1 and SEL1 genetic polymorphisms and remission in rheumatoid arthritis patients treated with TNF-\u03b1 inhibitors: a machine learning approach. Immunol Res 71(5):709\u2013716. https:\/\/doi.org\/10.1007\/s12026-023-09382-4","journal-title":"Immunol Res"},{"key":"5825_CR43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2024-eular.2784","volume":"83","author":"BY Kim","year":"2024","unstructured":"Kim BY, Koo J, Yeo J et al (2024) Machine learning-based prediction of treatment response to anti-tumor necrosis factor and janus kinase inhibitor therapies in patients with rheumatoid arthritis. Ann Rheum Dis 83:803\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.2784","journal-title":"Ann Rheum Dis"},{"key":"5825_CR44","doi-asserted-by":"publisher","first-page":"i154","DOI":"10.1093\/rheumatology\/keac133.281","volume":"61","author":"J Kimpton","year":"2022","unstructured":"Kimpton J, Shipa M, Yeoh SA et al (2022) Ana seroconversion during prior anti-tnf therapy abolishes anti-ccp antibody positivity as a predictor of abatacept retention in rheumatoid arthritis. Rheumatology (United Kingdom) 61:i154\u2013i155. https:\/\/doi.org\/10.1093\/rheumatology\/keac133.281","journal-title":"Rheumatology (United Kingdom)"},{"key":"5825_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02567-y","author":"BS Koo","year":"2021","unstructured":"Koo BS, Eun S, Shin K et al (2021) Machine learning model for identifying important clinical features for predicting remission in patients with rheumatoid arthritis treated with biologics. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/s13075-021-02567-y","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5825_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13075-021-02635-3","volume":"23","author":"S Lee","year":"2021","unstructured":"Lee S, Kang S, Eun Y et al (2021) Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Res Ther 23(1):254. https:\/\/doi.org\/10.1186\/s13075-021-02635-3","journal-title":"Arthritis Res Ther"},{"key":"5825_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/pds.5518","volume":"31","author":"A Liede","year":"2022","unstructured":"Liede A, Krueger W, Li L et al (2022) Predictors of effectiveness of first-line biologic disease modifying antirheumatic drug(s) (bDMARD) or targeted synthetic DMARD (tsDMARD) treatment with a tumor necrosis factor inhibitor in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf 31:80. https:\/\/doi.org\/10.1002\/pds.5518","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5825_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/pds.5518","volume":"31","author":"A Liede","year":"2022","unstructured":"Liede A, Krueger W, Li L et al (2022) Predictors of treatment changes in patients with rheumatoid arthritis using machine learning. Pharmacoepidemiol Drug Saf 31:134. https:\/\/doi.org\/10.1002\/pds.5518","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5825_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103800","author":"AJW Lim","year":"2022","unstructured":"Lim AJW, Lim LJ, Ooi BNS et al (2022) Functional coding haplotypes and machine-learning feature elimination identifies predictors of methotrexate response in rheumatoid arthritis patients. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103800","journal-title":"EBioMedicine"},{"issue":"10","key":"5825_CR50","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/rheumatology\/keac032","volume":"61","author":"LJ Lim","year":"2022","unstructured":"Lim LJ, Lim AJW, Ooi BNS et al (2022) Machine learning using genetic and clinical data identifies a signature that robustly predicts methotrexate response in rheumatoid arthritis. Rheumatology (United Kingdom) 61(10):4175\u20134186. https:\/\/doi.org\/10.1093\/rheumatology\/keac032","journal-title":"Rheumatology (United Kingdom)"},{"key":"5825_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/annrheumdis-2024-eular.4878","volume":"83","author":"C Lopez-Pedrera","year":"2024","unstructured":"Lopez-Pedrera C, Sanchez-Pareja I, Perez-Sanchez C et al (2024) The use of high-throughput technologies for molecular profiling in rheumatoid arthritis enables the identification of patient subgroups with distinctive disease activity and therapeutic response. Ann Rheum Dis 83:297. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.4878","journal-title":"Ann Rheum Dis"},{"key":"5825_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.631662","author":"M Luque-T\u00e9var","year":"2021","unstructured":"Luque-T\u00e9var M, Perez-Sanchez C, Pati\u00f1o-Trives AM et al (2021) Integrative clinical, molecular, and computational analysis identify novel biomarkers and differential profiles of anti-TNF response in rheumatoid arthritis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2021.631662","journal-title":"Front Immunol"},{"key":"5825_CR53","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/annrheumdis-2022-eular.4600","volume":"81","author":"T Maarseveen","year":"2022","unstructured":"Maarseveen T, Maurits M, Huizinga T et al (2022) Unsupervised deep-learning identifies six clinical subtypes of rheumatoid arthritis at baseline that associate with methotrexate failure during follow-up. Ann Rheum Dis 81:550\u2013551. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.4600","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5825_CR54","doi-asserted-by":"publisher","first-page":"7266","DOI":"10.1038\/s41598-021-86729-7","volume":"11","author":"M Maciejewski","year":"2021","unstructured":"Maciejewski M, Sands C, Nair N et al (2021) Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. Sci Rep 11(1):7266. https:\/\/doi.org\/10.1038\/s41598-021-86729-7","journal-title":"Sci Rep"},{"key":"5825_CR55","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/art.41966","volume":"73","author":"M Magrey","year":"2021","unstructured":"Magrey M, Ramiro S, Pinheiro MM et al (2021) Predictors of 1-year treatment response among upadacitinib-treated patients with ankylosing spondylitis: a post hoc analysis. Arthritis Rheumatol 73:1931\u20131933. https:\/\/doi.org\/10.1002\/art.41966","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"5825_CR56","doi-asserted-by":"publisher","first-page":"7224","DOI":"10.1038\/s41598-022-11361-y","volume":"12","author":"H Matsuo","year":"2022","unstructured":"Matsuo H, Kamada M, Imamura A et al (2022) Machine learning-based prediction of relapse in rheumatoid arthritis patients using data on ultrasound examination and blood test. Sci Rep 12(1):7224. https:\/\/doi.org\/10.1038\/s41598-022-11361-y","journal-title":"Sci Rep"},{"issue":"1","key":"5825_CR57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/nsm.2020.0007","volume":"3","author":"T Mellors","year":"2020","unstructured":"Mellors T, Withers JB, Ameli A et al (2020) Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients. Netw Syst Med 3(1):91\u2013104. https:\/\/doi.org\/10.1089\/nsm.2020.0007","journal-title":"Netw Syst Med"},{"key":"5825_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02560-5","author":"MA Messelink","year":"2021","unstructured":"Messelink MA, Roodenrijs NMT, van Es B et al (2021) Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/s13075-021-02560-5","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5825_CR59","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3109\/14397595.2016.1168536","volume":"26","author":"F Miyoshi","year":"2016","unstructured":"Miyoshi F, Honne K, Minota S et al (2016) A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab. Mod Rheumatol 26(6):813\u2013816. https:\/\/doi.org\/10.3109\/14397595.2016.1168536","journal-title":"Mod Rheumatol"},{"key":"5825_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2021.103842","author":"MA Morid","year":"2021","unstructured":"Morid MA, Lau M, Del Fiol G (2021) Predictive analytics for step-up therapy: supervised or semi-supervised learning? J Biomed Inform. https:\/\/doi.org\/10.1016\/j.jbi.2021.103842","journal-title":"J Biomed Inform"},{"issue":"6","key":"5825_CR61","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/acr.24834","volume":"74","author":"E Myasoedova","year":"2022","unstructured":"Myasoedova E, Athreya AP, Crowson CS et al (2022) Toward individualized prediction of response to methotrexate in early rheumatoid arthritis: a pharmacogenomics-driven machine learning approach. Arthritis Care Res 74(6):879\u2013888. https:\/\/doi.org\/10.1002\/acr.24834","journal-title":"Arthritis Care Res"},{"key":"5825_CR62","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/art.41966","volume":"73","author":"A Najm","year":"2021","unstructured":"Najm A, Sarda S, Toro M et al (2021) B cells repertoire repartition predicts response to methotrexate at 6 and 12 months in na\u00efve RA: a machine learning driven approach. Arthritis Rheumatol 73:2055\u20132056. https:\/\/doi.org\/10.1002\/art.41966","journal-title":"Arthritis Rheumatol"},{"key":"5825_CR63","doi-asserted-by":"publisher","first-page":"i108","DOI":"10.1093\/rheumatology\/keq725","volume":"49","author":"N Nishimoto","year":"2010","unstructured":"Nishimoto N, Kawata Y, Aoki C et al (2010) Responsiveness to tocilizumab in rheumatoid arthritis patients is predicted by gene expression profile in peripheral blood cells at baseline. Rheumatology 49:i108\u2013i109. https:\/\/doi.org\/10.1093\/rheumatology\/keq725","journal-title":"Rheumatology"},{"key":"5825_CR64","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/annrheumdis-2024-eular.2921","volume":"83","author":"A \u00d6bergSysojev","year":"2024","unstructured":"\u00d6bergSysojev A, Delcoigne B, Frisell T et al (2024) Impact of genetics on predicting persistence to treatment with methotrexate in early rheumatoid arthritis. Ann Rheum Dis 83:810. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.2921","journal-title":"Ann Rheum Dis"},{"key":"5825_CR65","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/annrheumdis-2024-eular.2825","volume":"83","author":"FT Perton","year":"2024","unstructured":"Perton FT, Spierings J, Pouw JN et al (2024) The development of a clinical prediction model for treatment response in individual psoriatic arthritis patients. Ann Rheum Dis 83:708\u2013709. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.2825","journal-title":"Ann Rheum Dis"},{"key":"5825_CR66","doi-asserted-by":"publisher","first-page":"ii78","DOI":"10.1093\/rheumatology\/kead104.158","volume":"62","author":"T Phillips","year":"2023","unstructured":"Phillips T, Bhandari M, Stammers M et al (2023) Machine-learning derived characteristics associated with tapering tnf inhibitors in individuals with rheumatoid arthritis. Rheumatology (United Kingdom) 62:ii78. https:\/\/doi.org\/10.1093\/rheumatology\/kead104.158","journal-title":"Rheumatology (United Kingdom)"},{"issue":"5","key":"5825_CR67","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.40810","volume":"71","author":"D Plant","year":"2019","unstructured":"Plant D, Maciejewski M, Smith S et al (2019) Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol 71(5):678\u2013684. https:\/\/doi.org\/10.1002\/art.40810","journal-title":"Arthritis Rheumatol"},{"key":"5825_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010204","author":"B Prasad","year":"2022","unstructured":"Prasad B, McGeough C, Eakin A et al (2022) ATRPred: A machine learning based tool for clinical decision making of anti-TNF treatment in rheumatoid arthritis patients. PLoS Comput Biol. https:\/\/doi.org\/10.1371\/journal.pcbi.1010204","journal-title":"PLoS Comput Biol"},{"key":"5825_CR69","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/annrheumdis-2023-eular.2722","volume":"82","author":"N Prenga","year":"2023","unstructured":"Prenga N, Nabi H, Steen Krogh N et al (2023) A machine learning model for identifying important clinical variables and predicting one-year treatment retention in patients with rheumatoid arthritis performing an infliximab biosimilar-to-biosimilar switch. Ann Rheum Dis 82:494. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.2722","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5825_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-022-02838-2","volume":"24","author":"R Queiro","year":"2022","unstructured":"Queiro R, Seoane-Mato D, Laiz A et al (2022) Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. Arthritis Res Ther 24(1):153. https:\/\/doi.org\/10.1186\/s13075-022-02838-2","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5825_CR71","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40744-021-00361-5","volume":"8","author":"M Rehberg","year":"2021","unstructured":"Rehberg M, Giegerich C, Praestgaard A et al (2021) Identification of a rule to predict response to sarilumab in patients with rheumatoid arthritis using machine learning and clinical trial data. Rheumatol Ther 8(4):1661\u20131675. https:\/\/doi.org\/10.1007\/s40744-021-00361-5","journal-title":"Rheumatol Ther"},{"key":"5825_CR72","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2016-eular.3108","volume":"75","author":"A Richter","year":"2016","unstructured":"Richter A, Pattloch D, Manger B et al (2016) Initiation of biologic treatment over the past 15 years reflects changes in treatment strategies: results from the prospective cohort of the German biologics register rabbit. Ann Rheum Dis 75:874\u2013875. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.3108","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5825_CR73","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","volume":"28","author":"F Rivellese","year":"2022","unstructured":"Rivellese F, Surace AEA, Goldmann K et al (2022) Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med 28(6):1256\u20131268. https:\/\/doi.org\/10.1038\/s41591-022-01789-0","journal-title":"Nat Med"},{"key":"5825_CR74","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-eular.3433","volume":"77","author":"C Ruiz-Romero","year":"2018","unstructured":"Ruiz-Romero C, Picchi F, Gonz\u00e1lez-Rodr\u00edguez L et al (2018) Identification of a protein panel useful for the prediction of response to methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 77:899\u2013900. https:\/\/doi.org\/10.1136\/annrheumdis-2018-eular.3433","journal-title":"Ann Rheum Dis"},{"key":"5825_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133890","author":"F Salehi","year":"2024","unstructured":"Salehi F, Lopera Gonzalez LI, Bayat S et al (2024) Machine learning prediction of treatment response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13133890","journal-title":"J Clin Med"},{"key":"5825_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152038","volume":"55","author":"MR Shipa","year":"2022","unstructured":"Shipa MR, Heyer N, Mansoor R et al (2022) Adalimumab or etanercept as first line biologic therapy in enthesitis related arthritis (ERA)\u2014a drug-survival single centre study spanning 10 years. Semin Arthritis Rheum 55:152038. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152038","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5825_CR77","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/rheumatology\/keab403","volume":"61","author":"MRA Shipa","year":"2022","unstructured":"Shipa MRA, Yeoh SA, Embleton-Thirsk A et al (2022) The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. Rheumatology (United Kingdom) 61(2):787\u2013793. https:\/\/doi.org\/10.1093\/rheumatology\/keab403","journal-title":"Rheumatology (United Kingdom)"},{"issue":"4","key":"5825_CR78","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/mr\/roac086","volume":"33","author":"MRA Shipa","year":"2023","unstructured":"Shipa MRA, Di Cicco M, Balogh E et al (2023) Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: choice of another tumour necrosis factor inhibitor or a biologic of different mode of action? Mod Rheumatol 33(4):700\u2013707. https:\/\/doi.org\/10.1093\/mr\/roac086","journal-title":"Mod Rheumatol"},{"key":"5825_CR79","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/art.40700","volume":"70","author":"D Sieghart","year":"2018","unstructured":"Sieghart D, Platzer A, Alasti F et al (2018) The prognostic value of autoantibody isotypes for predicting therapeutic responses to methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 70:2069\u20132070. https:\/\/doi.org\/10.1002\/art.40700","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"5825_CR80","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40744-024-00668-z","volume":"11","author":"K Sonomoto","year":"2024","unstructured":"Sonomoto K, Fujino Y, Tanaka H et al (2024) A machine learning approach for prediction of CDAI remission with TNF inhibitors: a concept of precision medicine from the FIRST registry. Rheumatol Ther 11(3):709\u2013736. https:\/\/doi.org\/10.1007\/s40744-024-00668-z","journal-title":"Rheumatol Ther"},{"key":"5825_CR81","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/annrheumdis-2023-eular.5874","volume":"82","author":"V Strand","year":"2023","unstructured":"Strand V, Mellors T, Jones A et al (2023) Assessment of clinical features as predictors of inadequate response to tnfi therapies-further analysis of the molecular signature response classifier. Ann Rheum Dis 82:485. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.5874","journal-title":"Ann Rheum Dis"},{"key":"5825_CR82","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-5791","author":"Z Sun","year":"2022","unstructured":"Sun Z, Wang F, Chen J et al (2022) Establishment and verification of a nomogram and a preliminary study on predicting the clinical response of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis patients. Ann Transl Med. https:\/\/doi.org\/10.21037\/atm-22-5791","journal-title":"Ann Transl Med"},{"key":"5825_CR83","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/03009742.2021.1951065","volume":"50","author":"NP Sundlis\u00e6ter","year":"2021","unstructured":"Sundlis\u00e6ter NP, Sexton J, Aga A et al (2021) Predictors of disease flare following tapering of conventional synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis remission. Scand J Rheumatol 50:10\u201311. https:\/\/doi.org\/10.1080\/03009742.2021.1951065","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"5825_CR84","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/art.41516","volume":"73","author":"W Tao","year":"2021","unstructured":"Tao W, Concepcion AN, Vianen M et al (2021) Multiomics and machine learning accurately predict clinical response to adalimumab and etanercept therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 73(2):212\u2013222. https:\/\/doi.org\/10.1002\/art.41516","journal-title":"Arthritis Rheumatol"},{"key":"5825_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0100-6","author":"TM Thomson","year":"2015","unstructured":"Thomson TM, Lescarbeau RM, Drubin DA et al (2015) Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis. BMC Med Genom. https:\/\/doi.org\/10.1186\/s12920-015-0100-6","journal-title":"BMC Med Genom"},{"key":"5825_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03277-x","author":"D Ukalovic","year":"2024","unstructured":"Ukalovic D, Leeb BF, Rintelen B et al (2024) Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/s13075-024-03277-x","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5825_CR87","doi-asserted-by":"publisher","first-page":"e22925","DOI":"10.1016\/j.heliyon.2023.e22925","volume":"10","author":"JL Valdivieso Shephard","year":"2024","unstructured":"Valdivieso Shephard JL, Alvarez Robles EJ, C\u00e1maraHij\u00f3n C et al (2024) Predicting anti-TNF treatment response in rheumatoid arthritis: an artificial intelligence-driven model using cytokine profile and routine clinical practice parameters. Heliyon 10(1):e22925. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22925","journal-title":"Heliyon"},{"key":"5825_CR88","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pds.4629","volume":"27","author":"T Vaul\u00e9on","year":"2018","unstructured":"Vaul\u00e9on T, Pau D, Darloy J et al (2018) Factors influencing treatment maintenance of SC and IV tocilizumab (TCZ) in patients with rheumatoid arthritis (RA) in real life. Pharmacoepidemiol Drug Saf 27:407. https:\/\/doi.org\/10.1002\/pds.4629","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5825_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.917939","volume":"13","author":"V Venerito","year":"2022","unstructured":"Venerito V, Lopalco G, Abbruzzese A et al (2022) A machine learning approach to predict remission in patients with psoriatic arthritis on treatment with secukinumab. Front Immunol 13:917939. https:\/\/doi.org\/10.3389\/fimmu.2022.917939","journal-title":"Front Immunol"},{"issue":"2","key":"5825_CR90","doi-asserted-by":"publisher","first-page":"E334","DOI":"10.1097\/RHU.0000000000001720","volume":"28","author":"V Venerito","year":"2022","unstructured":"Venerito V, Angelini O, Fornaro M et al (2022) A machine learning approach for predicting sustained remission in rheumatoid arthritis patients on biologic agents. J Clin Rheumatol 28(2):E334\u2013E339. https:\/\/doi.org\/10.1097\/RHU.0000000000001720","journal-title":"J Clin Rheumatol"},{"key":"5825_CR91","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/annrheumdis-2024-eular.5114","volume":"83","author":"V Venerito","year":"2024","unstructured":"Venerito V, Del Vescovo S, Cito A et al (2024) Harnessing the power of radiomics to predict persistence on TNFi therapy in patients with axial spondyloarthritis: a proof-of-concept study. Ann Rheum Dis 83:352\u2013353. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.5114","journal-title":"Ann Rheum Dis"},{"key":"5825_CR92","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1136\/annrheumdis-2021-eular.2717","volume":"80","author":"G Verhavert","year":"2021","unstructured":"Verhavert G, Verdonck T, Pazmino S et al (2021) Which prognostic factors might predict the need for treatment adaptation in early rheumatoid arthritis? A comparison of machine learning, survival analysis and regression methods. Ann Rheum Dis 80:1001\u20131002. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2717","journal-title":"Ann Rheum Dis"},{"key":"5825_CR93","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1136\/annrheumdis-2020-eular.1553","volume":"79","author":"A Vodencarevic","year":"2020","unstructured":"Vodencarevic A, Tascilar K, Hartmann F et al (2020) Prediction of flares for rheumatoid arthritis patients on biologic DMARDs using machine learning and subsets of variables available to physicians, patients and payers. Ann Rheum Dis 79:959\u2013960. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.1553","journal-title":"Ann Rheum Dis"},{"key":"5825_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/annrheumdis-2023-eular.229","volume":"82","author":"A Vodencarevic","year":"2023","unstructured":"Vodencarevic A, Brandt-Juergens J, Peterlik D et al (2023) Prediction of low disease activity in patients with ankylosing spondylitis treated with secukinumab in real world-data from the German aquila study. Ann Rheum Dis 82:38. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.229","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5825_CR95","doi-asserted-by":"publisher","first-page":"e222312","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang R, Dasgupta A, Ward MM (2022) Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open 5(3):e222312. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.2312","journal-title":"JAMA Netw Open"},{"issue":"7","key":"5825_CR96","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/acr2.11266","volume":"3","author":"H Westerlind","year":"2021","unstructured":"Westerlind H, Maciejewski M, Frisell T et al (2021) What is the persistence to methotrexate in rheumatoid arthritis, and does machine learning outperform hypothesis-based approaches to its prediction? ACR Open Rheumatol 3(7):457\u2013463. https:\/\/doi.org\/10.1002\/acr2.11266","journal-title":"ACR Open Rheumatol"},{"key":"5825_CR97","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/annrheumdis-2024-eular.552","volume":"83","author":"CF Yap","year":"2024","unstructured":"Yap CF, Nair N, Hyrich K et al (2024) Whole blood-based transcriptomic biomarkers for predicting adalimumab treatment response in rheumatoid arthritis identified through machine learning. Ann Rheum Dis 83:1661\u20131662. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.552","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5825_CR98","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/rheumatology\/keab521","volume":"61","author":"N Yoosuf","year":"2022","unstructured":"Yoosuf N, MacIejewski M, Ziemek D et al (2022) Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis. Rheumatology (United Kingdom) 61(4):1680\u20131689. https:\/\/doi.org\/10.1093\/rheumatology\/keab521","journal-title":"Rheumatology (United Kingdom)"},{"issue":"2","key":"5825_CR99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10067-022-06438-y","volume":"42","author":"S Zhang","year":"2023","unstructured":"Zhang S, Li P, Wu P et al (2023) Predictors of response of rituximab in rheumatoid arthritis by weighted gene co-expression network analysis. Clin Rheumatol 42(2):529\u2013538. https:\/\/doi.org\/10.1007\/s10067-022-06438-y","journal-title":"Clin Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05825-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05825-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05825-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T09:39:43Z","timestamp":1744709983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05825-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":99,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["5825"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05825-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diego Benavent, Jose Francisco Garc\u00eda Llorente, and Antonio G\u00f3mez-Centeno were paid consultants to Pfizer for their involvement in developing this manuscript and on the steering committee. Loreto Carmona, Teresa Ot\u00f3n, and Est\u00edbaliz Loza are employees of INMUSC, which Pfizer contracted to conduct and supervise the review. Maria Montoro and Susan Ramirez are Pfizer employees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"91"}}